anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a preparation technology and a production method of an integrated new dosage form of a Pinellia Tuber decoction. The raw materials for the effective components of the decoction comprise 3 parts by weight of Pinellia Tuber and 3 parts by weight of Poria cocos. The production method comprises the processes of ultrasonic airflow crushing, alcohol-water extraction, supersonic wave crushing extraction, water decoction and concentration, ultrasonic spray drying, nanometer grinding, high-pressure homogenization, nanoparticle preparation and the like. The advantages comprising multiple cooperation, multiple targeting and the like of a nanometer carrier combination technology are utilized in the invention. Great production cost reduction, great product quality improvement, medicine targeting strengthening, and medicine sustained and controlled release property strengthening are realized after the large-scale production. Internal and external administration can be simultaneously carried out, and the decoction can be respectively administrated in four time periods according to the midnight-noon ebb-flow and human qi and blood flow rules. The decoction can also be processed to prepare a film agent and a transdermal agent which are respectively plastered on different positions of a human body according to the midnight-noon ebb-flow and human qi and blood flow rules, and the effective components can be directly absorbed through skins.
To evaluate the efficacy (Objective Response Rate), safety and tolerability of 80mg Osimertinib eod dosing in NSCLC patients with sensitizing EGFR mutations and/or EGFR T790M resistance mutation that have no prior EGFR treatment.

To investigate the efficacy and safety of Osimertinib 80mg/eod. Parameters like PFS, DoR, the incidence of brain metastases and OS will be assessed for the efficacy using RECIST criteria version 1.1. PFS in the brain will be another endpoint. Adverse events will be graded according to CTCAE v4.0 by recording vital signs, physical examinations, weight, ECG, ECOG performance status, clinical chemistry, haematology, urinalysis. We would use ctDNA to detect the mutations and compare the progress of the disease or the outcome of patients besides clinical assessments. The relationship between PK and selected efficacy, pharmacodynamic markers (like duration of inhibition of EGFR by hair follicle sampling) and safety endpoints will be assessed as well.
Bifidobacterium animalis  and application of a compound bacterium preparation prepared from the  Bifidobacterium animalis  in the preparation of a medicine for treating or preventing avian influenza virus infection. The invention discovers that  Bifidobacterium animalis  ATCC Accession No. 25527 can be used for treating animals infected by H7N9, and after the  Bifidobacterium animalis  ATCC Accession No. 25527 is compounded with  Bifidobacterium pseudolongum  ATCC Accession No. 25526, the effect is better. The compound preparation can regulate the body immune response, remarkably improve the weight loss and lung tissue injury caused by H7N9 influenza virus infection, and obviously improve the survival rate of mice infected by H7N9 influenza virus. The compound probiotic preparation provided by the invention has a remarkable effect of resisting H7N9 influenza virus infection, and can be effectively used for preventing and treating avian influenza virus infection.
The primary purpose of this study is to determine whether treatment with pioglitazone can reduce serum levels of asymmetric dimethylarginine (ADMA) in patients with adult diabetes. Recent research has found that elevated serum ADMA is associated with increased cardiovascular events and mortality, particularly in people with diabetes (Boger 2005, Zoccali 2006, Ueda 2007). ADMA, by mediating nitric oxide (NO) availability, may trigger pro-atherogenic effects. High plasma concentration of this substance has been associated with intima-media thickening, left ventricular hypertrophy and all-cause and cardiovascular mortality in patients with end-stage renal disease, and associated with increased cardiovascular events in patients with diabetes (Kryzazanowska 2007). The result of higher levels of ADMA and reduced output of NO increases vasoconstriction, increases inflammation, and interferes with endothelial function. Preliminary studies indicate that pioglitazone may reduce ADMA levels, and thus lower cardiovascular risk.Thus, this protocol will test whether pioglitazone can reduce ADMA levels in adult patients with diabetes.
The invention discloses a poria cocos in vitro sperm nutrient solution, the preparation method and the application of the solution. The solution is mixed by polysaccharide extracted from poria cocos raw material and normal saline, wherein the ratio between the poria cocos polysaccharide and the normal saline is that 1 gram to 10 millimeter. The preparation method is: poria cocos raw material is cleaned, dried and smashed, and is drenched in normal saline; then the soak is put in a vessel, heated under conditions between 95 to 105 degrees centigrade, and filtered to produce poria cocos extract. The application of the poria cocos in vitro sperm nutrient solution is: the poria cocos in vitro sperm nutrient solution is mixed uniformly with semen with a liquid volume ratio of 1 to 1 to cultivate sperm and activated sperm. The invention is capable of enhancing the sperm mobility by 35 to 56 percent without any damage or side effects to sperm, so the product with such high effects can replace imported product. Besides, the price is greatly reduced compared with imported goods.
FIELD: medicine, gynecology, pharmacy. SUBSTANCE: invention relates to technology of medicinal forms containing bacterial preparations. Suppository has lyophilized lactobacteria and hydrophobic fat base consisting of emulsifier taken in the amount 4-6% of base mass. Suppository has also lactobacteria of the strain Lactobacillus fermentum VKMP B-7573 taken in the amount (0.8-4) x 10 8  bacterial cells per suppository. Hydrophobic fat mass with emulsifier has additionally soybean oil taken in the amount 4-6% of base mass. Highly hydrogenated plant oil, mainly palm (kernel) oil, cotton, sunflower, peanut or the composition "Vitepsol" can be used as hydrophobic fat base. Sodium salt of sulfoesters of higher saturated alcohols and sulfuric acid and/or monoglycerodistillate and/or triglycerol distearate are used as emulsifier. Invention provides the development of suppository used for treatment of patients with vagina dysbacteriosis. EFFECT: enhanced effectiveness, prolonged time of storage. 4 cl, 2 ex
Two forms of polypeptide growth factors have been purified to homogeneity from lyophilized powder of mature ewe kidneys. From 500 g of powder 8 to 14 mg of kidney derived growth factor (KDGF) was isolated. An 18,000 fold purification was accomplished with a 4 to 7% yield by a 6 step procedure that included an initial acetic acid extraction, heating at 95 DEG , Bio-Rad AG50W X8 cation exchange chromatography, 2 sequential DEAE-Sepharose CL-6B anion exchange steps at pH 5.8 and 6.2, respectively, and finally Sephadex G-50 chromatography in 0.1M acetic acid. From the Sephadex molecular sieve separation, the KDGF activity eluted in the same fractions as the single protein peak. Polyacrylamide gel electrophoresis analysis under non-reducing and non-denaturing conditions followed by Coomassie Blue staining confirmed a single band having a Mr 4,200. Molecular sieve HPLC done under acidic conditions confirmed a similar high (i.e. greater than 95%) degree of homogeneity. This preparation of KDGF was shown to be mitogenic for rat pituitary tumor cells, and hamster and rat kidney tumor cells, but not for normal rat diploid fibroblasts or low passage normal rat kidney (NRK) cells. The KDGF preparation that appeared greater than 90% homogeneous by the criteria described above was separated by chromatofocusing into 2 forms, KDGF-I and KDGF-II, of pI 5.2 and 4.8, respectively. Both forms showed Mr 4200. KDGF-II was the more abundant form, being 70% of the total KDGF isolated from the chromatofocusing elution. The G50s of KDGF-I and KDGF-Ii were 10 ng/ml (2.38x10-9M) and 19 ng/ml (4.52x10-9M), respectively, with the MTW9/PL cells in culture without any other additions to the serum free medium used in these bioassays.
Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response or partial response at any time after 4 cycles may discontinue study therapy to proceed to autologous or allogeneic stem cell transplant.
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterized by destruction of pancreatic β-cells, leading to insulin deficiency and hyperglycemia, and its incidence is increasing year by year. The pathogenesis of T1DM is complex, mainly including genetic and environmental factors. Intestinal flora is the largest microbial community in the human body and plays a very important role in human health and disease. In recent years, more and more studies have shown that intestinal flora and its metabolites, as an environmental factor, regulate the development of T1DM through various mechanisms such as altering the intestinal mucosal barrier, influencing insulin secretion and body immune regulation. Intestinal flora transplantation, probiotic supplementation, and other approaches to modulate the intestinal flora appear to be potential therapeutic approaches for T1DM. This article reviews the dysbiosis of the intestinal flora in T1DM, the potential mechanisms by which the intestinal flora affects T1DM, as well as discusses potential approaches to treating T1DM by intervening in the intestinal flora.
The aim of the study is to examine whether the pathologic status of SLNs in patients with early-stage cervical cancer correlates to the HPV status in the SLNs and also, whether cervical cancer recurrence correlates to the histopathologic status of the SLNs and/or the SLN HPV status.

In Denmark, staging and treatment of cervical cancer are performed according to the recommendations of the International Federation of Gynecology and Obstetrics (FIGO). Cervical cancer is the only gynecological cancer that is clinically based on tumor size, vaginal or parametrial involvement, bladder/rectum extension and distant metastases. It requires examination under anesthesia and imaging, which in Denmark includes positron emission computed tomography (PET-CT) to detect pathological lymph nodes (LNs) and to accurately delineate the extent of the disease and magnetic resonance imaging (MRI) to determine tumor size, degree of stromal penetration, parametrial involvement, vaginal and corpus extension. Tumor risk assessment includes tumor size, stage, depth of tumor invasion, LN status, lymphovascular space invasion (LVSI) and histological subtype, of which LN status and number of LNs involved are the most important prognostic factors. In Denmark, patients at FIGO stages 1B1 to 2A undergo radical hysterectomy and radical pelvic lymphadenectomy (PL), and they are offered adjuvant oncological treatment with radiotherapy and concomitant chemotherapy if specific risk factors are present. A national protocolled study on the implementation of SLN mapping in women with early-stage cervical cancer is currently being conducted in Denmark at Rigshospitalet, Odense University Hospital and Aarhus University Hospital (The Sentirec study). In this study, we want to examine the remains from these analyzed SLNs. According to the Sentirec protocol, SLNs are examined by means of ultrastaging, which entails cutting the SLNs in more sections and all levels of the LN and examining these levels histologically by an experienced pathologist. In this study, we examine the remains from the SLNs; that is the sections between the tissue used for SLN mapping. These sections are analyzed for HPV.
1. 5-(2-(4-(1,2-benzisothiazol-3-yl)piperazinyl-1-yl)ethyl)-6-chloro-1,3- dihydro-2H-indol-2-one mesylate trihydrate. 2. A pharmaceutical composition for the treatment of a psychotic disorder comprising an amount of the compound of claim 1 that is effective in the treatment of said psychotic disorder and a pharmaceutically acceptable carrier. 3. A method of treating a psychotic disorder in a mammal comprising administering to said mammal an amount of the compound of claim 1 that is effective in the treatment of said psychotic disorder. 4. The method of claim 3 wherein said psychotic disorder is schizophrenia, migraine pain or anxiety. 5. The method of claim 3 wherein said pyschotic disorder is schizophrenia. 6. The method of claim 3 wherein said administration is parenteral administration. 7. The method of claim 6 wherein said parenteral administration is intramuscular injection.
FIELD: microbiology, medicine. SUBSTANCE: strain Halobacterium halobium 35311 (VKPM B-1739) is recommended for preparing the preparation showing bioactive properties. This strain produces the broad spectrum of biological macrobiotic activity. Antiradical effect of preparation stops destructive effect of labile free radicals. Preparation is a lyophilized powder of halobacterium biomass and can be used as a biologically active addition to food, as an agent decreasing toxic effect of antitumor compounds. Preparation can be used for prophylaxis and therapy of radiation sickness. EFFECT: enhanced effectiveness of preparation.
The present invention is in the field of stem cell biology, in particular in the field of developmental and regenerative biology. The invention generally relates to a method of generating cells capable of differentiating to a multicellular organoid unit that morphologically and/or functionally resembles the terminal ductal-lobular unit. More precisely, said cells are generated by dissociating mammary epithelial tissue, thereby gaining cells and culturing said cells in presence of a compound which elevates cAMP levels in a collagen gel. Under said culturing conditions said cells form a multicellular organoid unit facilitating to obtain a breast stem cell by isolating a single cell from said multicellular organoid unit. The present invention also relates to enriching said cells and differentiating them to a multicellular organoid that morphologically and/or functionally resembles the terminal ductal-lobular unit and use of said cells or said multicellular organoid in testing a compound. Furthermore, the present invention relates to a composition comprising said breast stem cells or the multicellular organoid.
Intervention is going to take the form of a mindfulness-based internet intervention consisting of eight modules. The themes include awareness and nonjudgment of senses, emotions, and thoughts. These themes were chosen after considering topics that might be the most useful for individuals who experience post-traumatic disorder symptoms. Each module consists of psychoeducation and exercise (audio records mostly) parts. Psychologist can be reached on demand.

The effect of the intervention will be compared against a waiting list control group. Intervention is in Lithuanian.
OBJECTIVE: There is a growing consensus that the risks of current pharmacologic analgesics warrant consideration of alternative modalities for acute and chronic pain control. The objective of this study was to evaluate the effectiveness of transcutaneous electrical nerve stimulation (TENS) in adult emergency department (ED) patients presenting with abdominal pain.
METHODS: We conducted a patient and observer blinded randomized controlled trial comparing TENS to sham TENS. The study was conducted at a large suburban academic ED. Patients with abdominal pain and a verbal numeric pain scale (VNS) of 5 or greater were randomized to TENS or sham TENS applied via 4 skin pads, one in each abdominal quadrant for 30 min. The primary outcome was change in pain scores 30 min after the intervention. Our study had 80% power to detect a between group difference of 1.5 points on the VNS.
RESULTS: 81 patients were randomized to TENS (n = 41) or sham TENS (n = 40). Groups were similar in baseline characteristics. The mean (SD) reductions in pain scores were 1.9 (2.1) and 1.7 (2.6) in patients treated with TENS and sham TENS respectively (P = 0.81). Use of rescue medications in patients with treated with TENS and sham TENS was similar (49 vs 55% respectively, P = 0.66).
CONCLUSIONS: Application of TENS to the abdominal wall did not result in more effective pain relief than sham TENS in adult ED patients with abdominal pain.
In one aspect, the disclosure relates to stable emulsions incorporating an oil phase and an alcohol phase, wherein the emulsions contain one or more oxidative compounds, organic acids, and, optionally, skin conditioners, vitamins, fragrances, and the like. The emulsions are, in one aspect, useful as sanitizing lotions, moisturizing skin treatments, and makeup cleansers or removers. In another aspect, the emulsions are effective at sanitizing the skin but are non-drying and non-irritating. Also disclosed are single-phase liquid solutions incorporating at least one monoalcohol, a polyalcohol, and one or more oxidative compounds. In one aspect, the solutions are useful as cleansers for makeup and grooming tools. In another aspect, disclosed herein are methods of making the emulsions and solutions.
PURPOSE: A composition containing an Ulva fasciata Delile extract is provided to prevent and treat inflammation due to oxidative stress, such as inflammatory diseases including atopic dermatitis. CONSTITUTION: A pharmaceutical composition for preventing and treating inflammatory diseases contains 0.1-50 wt% of an Ulva fasciata Delile extract as an active ingredient. The extract is a crude extract, a polar solvent-soluble extract, or non-polar solvent soluble extract of Ulva fasciata Delile. The extract is prepared using water, C1-C4 alcohols, or a mixture thereof. An external use skin formulation for preventing and treating inflammatory diseases contains the extract as an active ingredient. [Reference numerals] (AA) Ulva pertusa; (BB) Ulva fasciata Delile
BACKGROUND: Cardiovascular disease (CVD) is a significant contributor to morbidity and mortality worldwide, with CVD and post-acute COVID-19 associated CVD increasing. It remains unknown whether COVID-19 patients with weight gain are at a high risk for CVD events. Therefore, the primary objective of this study is to investigate the association between weight control and the risk of CVD following COVID-19.
METHODS: The study included 2,024,728 adults who participated in two rounds of health screening between 2017 and 2020. The final cohort, which included 70,996 participants in the COVID-19 group and 212,869 participants in the control group. The adjusted hazard ratio of BMI change to CVD risk was calculated using Cox proportional hazards regression.
RESULTS: We identified a total of 2869 cases of CVD (861 events for COVID-19 group and 2,008 events for the control group). Compared to individuals with a stable BMI, COVID-19 patients without obesity had an increased risk of CVD (adjusted hazard ratio [aHR] = 2.28; 95% confidence interval [CI], 1.15-4.53; p-value = 0.018). Additionally, non-COVID-19 patients with obesity also exhibited a higher risk of CVD (aHR = 1.58; 95% CI, 1.01-2.47; p-value = 0.046).
CONCLUSION: In conclusion, people who gained weight during the pandemic, regardless of their weight category, had a significantly higher risk of CVD associated with COVID-19 compared to those who maintained their weight before the pandemic.
The present invention relates to an all-digestive tract microcapsule non-wound introduced diagnostic and examination system. The appearance has a capsule shape. An emulsion membrane compatible with the inner part of a human body is covered on the outer surface of the machine frame of the whole system; a miniature pressure sensor and a miniature temperature sensor arranged on the machine frame are respectively connected with an A/D converter by a signal amplifier; the A/D converter is connected with a special microprocessor chip connected with a signal wireless transmission functional module; a transmitting antenna is used for transmitting detection signals to the outer part of a body; the electricity of the system is supplied by a miniature battery. An extracorporeal signal reception system is used for receiving and storing the signals for real-time analysis or post-analysis as needed for outputting a result. In an examination process, the present invention makes a patient normally eat and work; the present invention is easily accepted by the patient. The whole examination process is completely in the state of normal physiology in the intestinal tract of a human body. Consequently, a measured parameter value has actuality and correctness.
All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. Pituitary down-regulation with GnRH agonist (triptorelin, 0.1mg/d, ×10d, then 0.05mg/d until E2 ≤40 pg/ml in serum), was initiated during the luteal phase on the cycle-day 21. Two weeks later, if E2 in serum was ≤40 pg/ml and absence of follicular activity was detected, the stimulation of ovaries was started by recombinant follicle-stimulating hormone (recFSH, Gonal-F, Serono, Switzerland) with doses ranging 150-250 IU/d. Doses were adjusted accordingly with ovarian monitoring and follicles growth. GnRHa (0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (0.05mg/d) was withheld in the study group. In the control group, GnRHa was used to the day of ovulation trigger. Ovulation was induced with HCG (5000-10000 IU) when at least three follicles greater than 16mm in diameter were detected on ultrasound examination and the leading follicles reached ≥ 18 mm in diameter. Oocytes retrieval for IVF or ICSI was performed 34-36 hours later under transvaginal ultrasound guidance.

Main Outcome Measure(s): Serum E2 levels, VEGF levels in Serum and follicular fluids, retrieved oocytes, fertilization, implantation rate and pregnancy rate (PR), the rate of OHSS.
Patients receive peposertib PO BID on days 2-21, mitoxantrone IV over 15 minutes, etoposide IV over 60 minutes and cytarabine IV over 60 minutes on days 1-5 in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo ECHO and MUGA during baseline, and blood collection and bone marrow biopsy throughout the study.